SCHEMBL84030

SCHEMBL84030

COC(=O)Oc1ccc([N+](=O)[O-])cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.62
BCL9 O00512 1/20 0.58
CTNNB1 P35222 1/20 0.58
HTR2A P28223 1/20 0.57
MGLL Q99685 2/20 0.55
ALDH1A1 P00352 4/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
MAPK1 P28482 2/20 0.53
LMNA P02545 2/20 0.53
TP53 P04637 1/20 0.53
CYP3A4 P08684 1/20 0.53
THRB P10828 1/20 0.53
HSD17B10 Q99714 1/20 0.53
KMT2A Q03164 4/20 0.53
PKM P14618 1/20 0.53
MAPT P10636 3/20 0.53
MEN1 O00255 3/20 0.52
HTT P42858 1/20 0.52
NPC1 O15118 1/20 0.51
RAB9A P51151 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Water SCHEMBL23006949 0.98 GAA (0.60) GAABCL9CTNNB1HTR2AMGLL
SCHEMBL7196970 0.95 GAA (0.60) GAABCL9CTNNB1HTR2AMGLL
SCHEMBL26374 0.88 GAA (0.65) GAABCL9CTNNB1HTR2AMGLL
SCHEMBL5024953 0.87 GAA (0.60) GAABCL9CTNNB1HTR2AALDH1A1
SCHEMBL15459741 0.87 HTR2A (0.53) GAABCL9CTNNB1HTR2AMGLL
Hydrochloric Acid SCHEMBL7895043 0.86 GAA (0.62) GAABCL9CTNNB1HTR2AMGLL
Acetic Acid SCHEMBL28965272 0.85 GAA (0.62) GAABCL9CTNNB1HTR2AMGLL
SCHEMBL13350950 0.85 GAA (0.54) GAABCL9CTNNB1MGLLALDH1A1
SCHEMBL14378853 0.85 GAA (0.61) GAABCL9CTNNB1HTR2AMGLL
SCHEMBL3176066 0.85 GAA (0.61) GAABCL9CTNNB1HTR2AMGLL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 347 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4448107-B1 DRUG DELIVERY SYSTEMS BASED ON ENDOPEROXIDES USEFUL IN DIAGNOSIS AND THERAPY, AND METHODS THEREOF FACULDADE DE FARMACIA DA UNIV DE LISBOA (PT) 2025-11-05 EP claimed
US-20250064840-A1 DRUG DELIVERY SYSTEMS BASED ON ENDOPEROXIDES USEFUL IN DIAGNOSIS AND THERAPY, AND METHODS THEREOF FACULDADE DE FARMÁCIA DA UNIVERSIDADE DE LISBOA (PT) 2025-02-27 US claimed
EP-4448107-A1 DRUG DELIVERY SYSTEMS BASED ON ENDOPEROXIDES USEFUL IN DIAGNOSIS AND THERAPY, AND METHODS THEREOF Faculdade de Farmácia da Universidade de Lisboa (PT) 2024-10-23 EP claimed
WO-2023111829-A1 DRUG DELIVERY SYSTEMS BASED ON ENDOPEROXIDES USEFUL IN DIAGNOSIS AND THERAPY, AND METHODS THEREOF FACULDADE DE FARMÁCIA DA UNIVERSIDADE DE LISBOA (PT) 2023-06-22 WO claimed
EP-1242059-B1 NOVEL PRODRUGS FOR ANTIMICROBIAL AMIDINES UNIV NORTH CAROLINA (US) 2007-03-21 EP claimed
US-6649652-B2 Hypotensive agents; hyperglycemic agents THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL 2003-11-18 US claimed
US-20030092755-A1 Novel prodrugs for antimicrobial amidines NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2003-05-15 US claimed
EP-1242059-A2 NOVEL PRODRUGS FOR ANTIMICROBIAL AMIDINES UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2002-09-25 EP claimed
US-20020019437-A1 Novel prodrugs for antimicrobial amidines NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2002-02-14 US claimed
WO-2001003685-A2 NOVEL PRODRUGS FOR ANTIMICROBIAL AMIDINES THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2001-01-18 WO claimed
US-12637441-B2 Prodrugs of the tyrosine kinase inhibitor for treating cancer Risen (Suzhou) Pharma Tech Co., Ltd. (CN) 2026-05-26 US disclosed
CN-122055369-A Bridged tricyclic carbamoyl pyridone compounds and uses thereof 吉利德科学公司 2026-05-15 CN disclosed
CN-122055373-A Bridged tricyclic carbamoyl pyridone compounds and uses thereof 吉利德科学公司 2026-05-15 CN disclosed
EP-4281083-B1 COMBINATION THERAPY FOR HIV WITH ADENOSINE DERIVATIVE AND CAPSID INHIBITORS BRII BIOSCIENCES INC (US) 2026-05-13 EP disclosed
WO-2026090173-A1 MODIFIED SELF-IMMOLATING MOIETIES IN ANTIBODY-DRUG CONJUGATES CODEABLE THERAPEUTICS, INCORPORATED (US) 2026-04-30 WO disclosed
EP-0215942-A4 POLYNUCLEOTIDE ASSAY REAGENT AND METHOD. SUMMERTON JAMES 1988-08-23 EP disclosed
EP-0216860-A1 STEREOREGULAR POLYNUCLEOTIDE-BINDING POLYMERS. SUMMERTON JAMES (US) 1987-04-08 EP disclosed
EP-0215942-A1 POLYNUCLEOTIDE ASSAY REAGENT AND METHOD. SUMMERTON JAMES 1987-04-01 EP disclosed
WO-1986005519-A1 POLYNUCLEOTIDE ASSAY REAGENT AND METHOD SUMMERTON JAMES 1986-09-25 WO disclosed
WO-1986005518-A1 STEREOREGULAR POLYNUCLEOTIDE-BINDING POLYMERS SUMMERTON JAMES 1986-09-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12637441-B2 Prodrugs of the tyrosine kinase inhibitor for treating cancer EGFR, ERBB2, MET GAA 2674/4885BCL9 361/4885CTNNB1 1180/4885
US-20250064840-A1 DRUG DELIVERY SYSTEMS BASED ON ENDOPEROXIDES USEFUL IN DIAGNOSIS AND THERAPY, AND METHODS THEREOF FECH, PTGIS, EPHX1 GAA 2049/4885BCL9 2027/4885CTNNB1 3232/4885
US-20030092755-A1 Novel prodrugs for antimicrobial amidines NR1H3, APEH, NR1H2 GAA 1600/4885BCL9 2630/4885CTNNB1 4432/4885
US-20020019437-A1 Novel prodrugs for antimicrobial amidines NR1H3, APEH, NR1H2 GAA 1600/4885BCL9 2630/4885CTNNB1 4432/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.